All News
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia
Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months.
Read Article
RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are there benefits to diet or vegan diets? What's the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month.
Read Article
How to assess ILD in your patients?
Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory myositis), and rheumatoid arthritis.
Read Article
Antifibrotics - A New Class of Therapies in Rheumatology?
Rheumatologists typically manage systemic autoimmune rheumatic diseases (SARD) and associated interstitial lung disease (ILD) with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic agents in this setting.
Read Article
Evidence of immune ageing detected at the earliest stages of RA. Study of 69 controls, 32 CSA, 44 undiff. arthritis (UA), 23 early RA, & 56 DMARD naive RA. UA & CSA had reduced naive CD4 T cells. Th17, Tregs &7 senescent T cells, were only seen once RA was established. https://t.co/c1wiA5gvM5
Dr. John Cush RheumNow ( View Tweet)
SMART study - Single vs. Split Dose Methotrexate in RA
Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients.
https://t.co/JN5wPGNjao https://t.co/lizsrtVHwf
Dr. John Cush RheumNow ( View Tweet)
Future Perspectives of Rheumatoid Arthritis
Dr. Kuni Yamaoka, shares highlights from the Future Perspectives of Rheumatoid Arthritis session at the APLAR 2025 Congress in Fukuoka, Japan.
https://t.co/LGLqe48R2L https://t.co/Kwp3cFPtyw
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Progressive RA-ILD Management
Dr. Richard Conway, a rheumatologist in Dublin, discusses a case about managing progressive rheumatoid arthritis-interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September https://t.co/dLCXeXwl7w
Dr. John Cush RheumNow ( View Tweet)
How to treat CTD ILD?
A comparative slide summarizing ACR/BSR and EULAR treatment guidelines
Emphasis on combination of Immunosuppressant and Antifibrotics
@RheumNow #APLAR25 https://t.co/gLSht6QKh5
Aurelie Najm AurelieRheumo ( View Tweet)
Peter Taylor on extra articular manifestations of RA
Keep an eye on RA patients’ glomerular function
RA patients have increased risk of CKD
Systematic review >1million pts
Risk Ratio 1.52
@RheumNow #APLAR25 https://t.co/5iZwtmvwSR
Aurelie Najm AurelieRheumo ( View Tweet)
QD Clinic Video: RA and Bronchiectasis
Dr. Jeffrey Sparks, Boston, talks about rheumatoid arthritis and bronchiectasis as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/Y2u3m4rFfj https://t.co/KgrIxXlQo4
Dr. John Cush RheumNow ( View Tweet)
STOP-RA results published in A&R. 144 at risk, CCP+ pts were enrolled to received HCQ vs PBO for 12 mos, w/ 24 mos F/U. Progression to RA seen in 30.4% on HCQ vs 32.9% on PBO (NS; P=0.52). Also IA, Jt Sxs, severity & adverse events were similar between groups.
Dr. John Cush RheumNow ( View Tweet)
Flow cytometry on Peripheral blood can help patient stratification in RA
A cluster rich in TEMRA Terminally Differentiated Effector Memory T Cells is associated with response to treatment and therapeutic decision taking into account showed higher remission 39% vs. 24%
Next https://t.co/8ZZ2epf7LK
Aurelie Najm AurelieRheumo ( View Tweet)
2025 Update of EULAR RA management recommandation
Summary slide inspired from Josef Smolen’s presentation
@RheumNow #APLAR25 https://t.co/wRzeX9OIry https://t.co/djrd7O9G9H
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Single center study of 47 RA-ILD pts (Dx Age 64.7 yrs; 30 mos F/U). Median 100 mos from RA Dx to RA-ILD. Nearly half (49%) recv Rx for RA-ILD; few w/ TCZ, nintedanib, pirfenidone. ~90% had RA-ILD stability/improve @ 6 & 12 mos. Progression assoc w/ tobacco use (P .025) @ 6 mos https://t.co/AK4zYgcxeK
Dr. John Cush RheumNow ( View Tweet)
Regional Disparities in DMARD Management for RA Treatment
Dr. Aurelie Najm, Glasgow, reports on a session on "Updates on DMARDs treatment: global standards and regional adaptations" from the APLAR 2025 Congress in Fukuoka, Japan.
https://t.co/zDo5NxKtbE https://t.co/kF9FxyWkIQ
Dr. John Cush RheumNow ( View Tweet)
A new player in AIRD
ThA age associated T helper cells
Displaying both Cytotoxic & APC functions
Correlation with disease activity in RA and SLE
More research is needed to better characterize function but could be a promising therapeutic target
@RheumNow #APLAR25 https://t.co/4SnY65tXpJ
Aurelie Najm AurelieRheumo ( View Tweet)
#APLAR2025 Prof Peter Taylor
RA patients have ⬆️ rates of CKD https://t.co/DZl9qpbLhH
Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
Stay sharp in RA, PsA & SpA care. Get the latest breakthroughs + expert insights at RWCS 2026. Don’t miss 'Year in Review: Rheumatology Advances.' Register now: https://t.co/majEsY4tXK https://t.co/fgGniR1OGk
RWCS RWCSmtg ( View Tweet)
Metanalysis of 7 studies (1979-2023) shows RA pts on vegetarian or vegan diets achieved no improvement in disease activity or physical function, but did have a small significant improvement in pain. Insufficient Data on Fatigue. Overall, low certainty https://t.co/jeh6gN5Byg
Dr. John Cush RheumNow ( View Tweet)
